Protalix BioTherapeutics (PLX) Shares Outstanding (Diluted Average) (2012 - 2025)

Protalix BioTherapeutics' Shares Outstanding (Diluted Average) history runs 12 years deep, the most recent figure standing at $76.6 million for Q1 2025.

• In Q1 2025, Shares Outstanding (Diluted Average) rose 4.9% year-over-year to $76.6 million; the TTM figure through Mar 2025 stood at $76.6 million (up 4.9% YoY), while the FY2022 annual figure was $48.5 million, up 9.81% from the prior year.
• Shares Outstanding (Diluted Average) was $76.6 million for Q1 2025 at Protalix BioTherapeutics, up from $73.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $83.2 million in Q2 2023 to a low of $39.9 million in Q1 2021.
• Historically, Shares Outstanding (Diluted Average) has averaged $55.8 million across 5 years, with a median of $47.6 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) surged 75.8% in 2023, then slipped 12.05% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $44.1 million in 2021, then grew by 9.81% to $48.5 million in 2022, then soared by 71.65% to $83.2 million in 2023, then dropped by 12.05% to $73.2 million in 2024, then gained by 4.7% to $76.6 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $76.6 million (Q1 2025), $73.2 million (Q2 2024), and $73.0 million (Q1 2024), per Business Quant data.